Recent articles from Anastasiia
Neurotech Trends in 2025: When Use Cases Started Driving Design
Neurotechnology development in 2025 showed a shift from exploratory demonstration toward systems engineered around specific clinical and research uses. Across brain–computer interfaces, neuromodulation, diagnostics, and experimental neuroscience, design choices increasingly reflected where and how technologies are meant to operate, whether …
Tempus Launches Paige Predict, Following $81M Paige AI Acquisition
Tempus has introduced Paige Predict, a new suite of AI-based digital pathology tools that analyze standard hematoxylin and eosin (H&E) stained tissue slides to estimate the likelihood of biomarker presence. The system is designed to guide molecular test ordering …
“ChatGPT for Doctors” Raises $250M Series D at $12B Valuation
OpenEvidence, a specialized AI-powered medical search engine, has raised $250 million in a Series D financing round led by Thrive Capital and DST Global, valuing the company at $12 billion and bringing total capital raised to roughly $700 million. The …
BioAge to Begin Mid-2026 Trial of Oral NLRP3 Inhibitor in Diabetic Macular Edema
BioAge Labs will expand clinical development of its oral brain-penetrant small molecule NLRP3 inhibitor, BGE-102, into ophthalmology, initiating a Phase 1b/2a proof-of-concept trial in patients with diabetic macular edema (DME) by mid-2026. The study is designed to assess ocular …
In a $66M Deal, Insilico Medicine and Hygtia Will Develop an AI-Designed Brain-Penetrant NLRP3 Inhibitor for CNS Diseases
Insilico Medicine and Hygtia Therapeutics have entered a global co-development and licensing agreement for ISM8969, an orally available, blood-brain barrier–penetrant NLRP3 inhibitor intended for central nervous system (CNS) disorders such as Parkinson’s and Alzheimer’s disease. Discovered via Insilico’s generative …
Isomorphic Labs and Johnson & Johnson Partner on AI-Driven, Multi-Modality Drug Discovery
Isomorphic Labs has announced a cross-modality research collaboration with Johnson & Johnson, aimed at integrating its AI-based drug design engine with Johnson & Johnson’s experimental and clinical development infrastructure. The deal involves multi-target discovery work across modalities such as …
Scribe to Start First Human Trial of One-Time CRISPR Therapy for Cardiovascular Disease
Scribe Therapeutics is preparing to enter the clinic in mid-2026 with Phase 1 studies of STX-1150, a one-time CRISPR-based therapy designed to silence genes linked to high cholesterol without cutting DNA. The therapy aims to durably suppress LDL cholesterol …
BMS Taps Immunai’s AI Immune Atlas To Decode Clinical Trial Responses
Immunai has entered a strategic collaboration with Bristol Myers Squibb (BMS) to apply its AI-powered operating system, AMICA-OS, in support of BMS’s clinical development programs. The partnership focuses on leveraging Immunai’s immune-mapping infrastructure and analytical models to generate insights …
Google Updates Open Medical AI Suite With New Imaging and Speech Models, Launches $100K Developer Hackathon
Google has released updates to its open-source medical AI suite with MedGemma 1.5 4B and a new speech-to-text model, MedASR, and introduced the MedGemma Impact Challenge, a hackathon hosted on Kaggle offering $100,000 in prizes. The new models …
Tahoe, Arc Institute, and Biohub Collaborate to Release Largest Open Dataset for Virtual Cell Modeling
Tahoe Therapeutics (formerly Vevo), Arc Institute, and CZI’s Biohub have announced a joint initiative to generate what is reportedly the largest and most perturbation-rich single-cell dataset available for virtual cell model development. The dataset will comprise over 120 million single-cell …